CBUS vs DNA
CBUS: Cibus is an agricultural biotechnology company that uses precision gene editing to help seed companies create higher-yielding, more resilient crops faster than traditional breeding. DNA: Ginkgo Bioworks provides an AI-enabled, robotically automated platform designed to make biological research, cell programming, and manufacturing easier and faster for its customers.
Side-by-side fundamentals
| Metric | CBUS | DNA | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $1.39 | $9.86 | |
| Market cap | $106M | $628M | |
| Net margin FY2025, SEC XBRL | -3492.3% | -183.8% | DNA higher |
| Gross margin FY2022, SEC XBRL | +100.0% | n/a | |
| Operating margin FY2025, SEC XBRL | -2680.1% | -185.3% | DNA higher |
| ROE FY2025, SEC XBRL | -582.2% | -61.5% | DNA higher |
| ROA FY2025, SEC XBRL | -41.7% | -27.9% | DNA higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.06 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | -14.6% | -25.1% | CBUS higher |
| Revenue CAGR (3y) SEC XBRL | +185.1% | -29.1% | CBUS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.81 | 2.40 | |
| 1-year return as of 2026-10-20 close | -16.3% | -27.7% | CBUS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.